New Jersey-based Merck & Co. Inc. MRK is a global research-driven pharmaceutical products company. Well known products in Merck’s portfolio include Remicade, Nasonex, Simponi, Vytorin and Zetia, Januvia and Janumet, Isentress, Emend, Keytruda, Cozaar/Hyzaar, Zocor, ProQuad, Gardasil, Zostavax and others.
However, like many of its peers, Merck is facing headwinds in the form of generic competition for several key products.
Merck’s performance has been pretty impressive, with the company exceeding earnings expectations in all the trailing four quarters. The average positive earnings surprise over the last four quarters is 3.13%. Earnings estimates have increased slightly over the past 60 days.
Currently, Merck has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Merck surpassed earnings expectations. The company reported EPS of $1.22 while our consensus called for EPS of $1.05. Earnings rose 16% year over year (up 18% excluding the impact of currency)
Revenues Beat: Revenues in the reported quarter also came above expectations. Merck posted revenues of $10.8 billion also above our consensus estimate of $10.32 billion.
Key Stats: The Pharmaceutical segment generated revenues of $9.66 billion, up 6% (up 12% excluding Fx impact) year over year as higher sales in oncology and vaccines were offset by lower sales in virology.
Keytruda, the largest product in Merck’s portfolio, brought sales of $2.27 billion in the quarter, up around 5.6% sequentially and 55% year over year.
2019 Outlook: Merck raised earnings and sales guidance for 2019.
Merck expects revenues to be in the range of $43.9 billion – $45.1 billion (previously $43.2 billion – $44.7 billion). The Zacks Consensus Estimate stood at $44.31 billion. Adjusted earnings are expected to be in the range of $4.67–$4.79 (previously $4.57–$4.72). The Zacks Consensus Estimate stood at $4.65 per share. While revenue guidance includes slightly more than 1% negative impact of currency fluctuation, earnings guidance includes a slightly positive impact.
Stock Price Impact: Shares were up more than 2.2% in pre-market trading.
Merck & Co., Inc. Price and EPS Surprise
Merck & Co., Inc. Price and EPS Surprise | Merck & Co., Inc. Quote
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research